|Targets||Protease-Activated Receptors (PARs)|
|Description||LRGILS-NH is a control peptide for SLIGRL-NH2, a protease-activated receptor-2 (PAR2) agonist that facilitates gastrointestinal transit in vivo.|
|Purity||≥95% by HPLC|
UDM-002555 is a small-molecule and selective antagonist of protease-activated receptor-4 (PAR-4). It can suppress the activation of platelet in dose manner. In ...
GB 83 is a selective antagonist of human protease activated receptor 2 (PAR2) (IC50 = 2 mM).
FR 171113 is a protease-activated receptor 1 (PAR1) antagonist displaying significant antiplatelet activity in vitro. It inhibits thrombin TRAP-6-induced platel...
Thrombin Receptor Activator Peptide 6
TRAP-6, a peptide compound, has been found to be a PAR1 agonist and could also influence the phosphorylation of rapid phosphodiesterase 3A in the positive way.
FSLLRY-NH2 is a selective PAR2 peptide antagonist. It reverses taxol-induced mechanical allodynia, heat hyperalgesia and PKC activation in ICR mice, also suppre...
BMS-986141 is a dual antagonist of proteinase-activated receptor 1 (PAR1) and PAR4. BMS-986141 was confirmed in cynomolgus monkeys to be a better therapy for pr...
LRGILS-NH is a control peptide for SLIGRL-NH2, a protease-activated receptor-2 (PAR2) agonist that facilitates gastrointestinal transit in vivo.
BMS-986120, an imidazoles derivative, has been found to be a PAR4 antagonist that could probably be effective against thrombus propagation and pathological vasc...